VEGFA and neoplasm: Several agents inhibiting the VEGF signaling cascade, such as sorafenib, sunitinib, axitinib, pazopanib and bevacizumab, have been found to exert significant anti-tumor effects and provide meaningful clinical benefit [7,8,9,10,11].